TY - JOUR
T1 - Concomitant administration of recombinant human interleukin-2 and recombinant interferon -α-2a in cancer patients
T2 - a phase I study
AU - Lee, K. H.
AU - Talpaz, M.
AU - Rothberg, J. M.
AU - Murray, J. L.
AU - Papadopoulos, N.
AU - Plager, C.
AU - Benjamin, R.
AU - Levitt, D.
AU - Gutterman, J.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 1989
Y1 - 1989
N2 - Twenty-seven patients with metastatic cancer were treated with a daily continuous intravenous (IV) infusion of recombinant human interleukin-2 (rhIL-2) along with daily intramuscular recombinant interferon-alpha-2a (rIFN-α-2a) 4 days per week for 4 weeks with repeated treatment after 2 to 4 weeks of rest. The maximum-tolerated dose (MTD) was 3 million U/m2/d of rhIL-2 with 5 to 10 million U/m2/d of rIFN-α-2a. The dose-limiting toxicities are moderate hypotension requiring low doses of pressors and chronic fatigue associated with decreased performance status. Other common side effects included fever, chills, fluid retention, nausea/vomiting, erythrodermia, weight loss, elevated liver transaminase levels, anemia, thrombocytopenia, and CNS toxic effects. There were seven objective responses among 25 evaluable patients. Four major responses (one complete response and three partial responses) were observed among 10 patients with melanoma treated with the MTD level. These data suggest that for cancer patients, concomitant rhIL-2 and rIFN-α-2a therapy is tolerable and has manageable side effects. Further phase II studies will be needed to define the antitumor activity of this combination.
AB - Twenty-seven patients with metastatic cancer were treated with a daily continuous intravenous (IV) infusion of recombinant human interleukin-2 (rhIL-2) along with daily intramuscular recombinant interferon-alpha-2a (rIFN-α-2a) 4 days per week for 4 weeks with repeated treatment after 2 to 4 weeks of rest. The maximum-tolerated dose (MTD) was 3 million U/m2/d of rhIL-2 with 5 to 10 million U/m2/d of rIFN-α-2a. The dose-limiting toxicities are moderate hypotension requiring low doses of pressors and chronic fatigue associated with decreased performance status. Other common side effects included fever, chills, fluid retention, nausea/vomiting, erythrodermia, weight loss, elevated liver transaminase levels, anemia, thrombocytopenia, and CNS toxic effects. There were seven objective responses among 25 evaluable patients. Four major responses (one complete response and three partial responses) were observed among 10 patients with melanoma treated with the MTD level. These data suggest that for cancer patients, concomitant rhIL-2 and rIFN-α-2a therapy is tolerable and has manageable side effects. Further phase II studies will be needed to define the antitumor activity of this combination.
UR - http://www.scopus.com/inward/record.url?scp=0024433613&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024433613&partnerID=8YFLogxK
U2 - 10.1200/JCO.1989.7.11.1726
DO - 10.1200/JCO.1989.7.11.1726
M3 - Article
C2 - 2809685
AN - SCOPUS:0024433613
SN - 0732-183X
VL - 7
SP - 1726
EP - 1732
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 11
ER -